Extranodal NK/T-cell lymphoma, nasal type
Extranodal NK-T-cell lymphoma | |
---|---|
Other names | Angiocentric lymphoma, Nasal-type NK lymphoma, NK/T-cell lymphoma, Polymorphic/malignant midline reticulosis |
Histopathology of extranodal NK-T cell lymphoma, nasal type (H&E stain).[1] These lymphoma cells are typically monotonous, with folded nuclei, indistinct nucleoli and moderate amount of cytoplasm.[2] | |
Specialty | Hematology and Oncology |
Causes | Epstein–Barr virus |
Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) (also termed angiocentric lymphoma, nasal-type NK lymphoma, NK/T-cell lymphoma, polymorphic/malignant midline reticulosis,
ENKTCL-NT is classified as an
Epstein-Barr virus-positive nodal NK/T cell lymphoma (EBV+ nodal NKTCL) was considered to be one form of ENKTCL-NT since it is a malignancy of EBV-infected NK or T cells. However, EBV+ nodal NKTCL is manifested primarily by its involvement in
While a rare disease, particularly in North America, ENKTCL-NT has recently gained much interest. Clinical studies have found that newer
Presentation
Extranodal NK/T-cell lymphoma, nasal type occurs primarily in Asians and South Americans; it is comparatively uncommon in other areas. Affected patients (median age 50–60 years old; males predominate) most often (~80% of cases) present with nasal bleeding, upper airway obstruction, perforation of the
About 45% of patients present with elevated levels of serum
Pathogenesis
Disease location
ENKTCL-NT is a disease of malignant NK or, very much less often,
Genes
ENKTCL-NT is thought to arise from the expression of EBV genes in the infected NK or cytotoxic T cells and the ability of these genes to cause the cells they infect to overexpress and acquire mutations in key genes that regulate cell growth, immortalization, invasiveness, and ability to evade normal control mechanisms, particularly immune surveillance. Since these gene-related abnormalities are multiple and vary between patients, it is not clear which contribute to the development and/or progression of ENKTCL-NT. Clinical studies are therefore examining targeted therapy tactics to determine which gene abnormalities contribute to, and which drugs targeting these abnormalities are useful in treating, ENKTCL-NT.[18]
EBV genes
Infected cells carry ~10 cytosolic EBV
Infected cell genes
The rapidly proliferating and immortalized EBV-infected NK/T cells accumulate numerous changes in the expression or activity of their genes by acquisition of chromosome deletions, gene mutations, and changes in gene expression.[citation needed]
Chromosomes
Mutated genes
Gene | Product | Mutation rate | Function | Mutation type | Influence on cell function | Clinical impact on ENKTCL-NT |
---|---|---|---|---|---|---|
TP53 |
p53 | 13–62% | tumor suppressor |
gain | promotes cell proliferation, survival, migration, invasiveness, and metastasis | correlates with advanced stage and poor prognosis[18] |
DDX3X | DDX3X | 12–20% | tumor suppressor | loss |
lost ability to inhibit proliferation | correlates with advanced stage and poor prognosis[18] |
STAT3 | STAT3 | 8–26% | JAK-STAT signaling pathway component | gain | promotes cell proliferation and survival | unknown[18] |
STAT5B | STAT5B | ~2–6% | JAK-STAT signaling pathway component | gain | promotes cell proliferation and survival | unknown[18] |
JAK3 |
JAK3 | 0–35% | JAK-STAT signaling pathway component | gain | promotes cell proliferation and survival | unknown[18] |
MGA | MAX dimerization protein | ~8% | tumor suppressor | loss | unknown | unknown[18] |
MLL2 |
MLL2 | 7–80% | histone methyltransferase, tumor suppressor | loss | reduces cellular differentiation, possibly promoting cell proliferation and survival | unknown[18] |
BCOR | BCL-6 corepressor | 21–32% | inhibits BCL-5, may regulate apoptosis | loss | may increase cell survival | unknown[18] |
ECSIT | ECSIT | 19% | element in TGF-β/BMP/signaling pathways | gain | activates NF-κB to promote cell survival and prolifaration | correlates with advanced stage and poor prognosis[12] |
ARID1A | ARID1A | 4–8% | a SWI/SNF protein that regulates expression of other proteins | loss | unknown | unknown[18] |
MCL1 | MCL1 | most cases | a SWI/SNF protein that regulates expression of other proteins | loss | unknown | unknown[18] |
In the above table, ARID1A protein stands for AT-rich interactive domain-containing protein 1A and ECSIT protein stands for evolutionarily conserved signaling intermediate in Toll pathway; mitochondrial. A gain of function mutation in the ECSIT gene that changes the amino acid at the 140 position in its product protein from
Overexpressed genes
ENKTCL-NT malignant cells overexpress
Signaling pathways
In consequence of, or addition to the cited genetic abnormalities, ENKTCL-NT malignant cells have overly active the; JAK-STAT signaling pathway that in the cancer setting promotes cell proliferation, survival, and other pro-malignant behaviors;[14] platelet-derived growth factor signaling pathway that in the cancer setting promotes cell survival and proliferation; Notch signaling pathway that in the cancer setting promotes cellular differentiation and proliferation; and NF-κB signaling that in the cancer setting promotes cell survival and proliferation. Studies suggest that that overactive VEGF receptor and Protein kinase B signaling pathways may also play a role in the pathogenesis of ENKTCL-NT.[12])
Epigenetic abnormalities
Studies on cultured malignant NK cells and/or patient tissue specimens find that numerous genes are
Histology
On microscopic examination, involved tissues show commonly show areas of
Diagnosis
The diagnosis of ENKTCL-NT depends on histological findings that biopsied tissue infiltrates contain lymphocytes that express CD3ε, cytotoxic molecules (granzyme B, perforin, TIA1), and EBV.[12] Bone marrow examination is recommended to determine its involvement in this disorder. Whole body PET-CT scans are recommended to determine the extent of disease at presentation as well as to follow the effects of therapeutic interventions. The tumor load of each individual's disease as well as response to therapies has also been estimated by assaying plasma levels of EBV DNA.[14] ENKTCL-NT can be mimicked by two benign diseases which involve the excessive proliferation of non-malignant NK cells in the GI tract viz., Natural killer cell enteropathy, a disease wherein NK cell infiltrative lesions occur in the intestine, colon, stomach, and/or esophagus, and lymphomatoid gastropathy, a disease wherein these cells infiltrative lesions are limited to the stomach.[26] Another lymphoproliferative disorder of the GI tract, indolent T cell lymphoproliferative disorder of the gastrointestinal tract may also mimic ENKTCL-NT. This chronic disorder involves the proliferation of CD+4, CD8+, CD4-/CD8-, or CD4+/CD8+ T cells in the mucosal layers of the GI tract to give a variety of GI tract symptoms. While generally a persistent and benign disorder, a small but significant percentage of cases have progressed to aggressive lymphomas.[27][28]
Course of ENKTCL-NT
The course of the untreated disease is heavily dependent on its clinical stage at diagnosis. Patients presenting with highly localized stage I nasal disease usually have nasal but no other symptoms; these individuals commonly show no progression of their disease over long periods of time. Other patients with limited (i.e. stage I or II) disease involving other sites in the head area are more likely to have a relatively slow progression of their disease while patients with stage III or IV disease have a more rapidly progressive disease with a poor prognosis. Patients presenting with ENKTCL-NT that does not involve the head area typically have a disseminated and aggressively progressive disease with a very poor prognosis.[13] Patients with stage I or II localized disease that have been treated with the recently defined chemotherapeutic protocols have 5 year survivals of ~70–89%[11] while those with advanced stage III or IV disseminated disease treated with these protocols have 5 year survivals of 50%.[25] Patients who relapse or are resistant to these protocols have had overall survivals of just a few months.[11]
Three prognostic models, NK-PI, PINK (i.e. prognostic index of natural killer lymphomas), and PINK-E) for ENKTCL-NT have evolved over the past 12 years. The latest model, PINK-E, which applies to patients treated with recently defined regimens, lists 5 risk factors (age >60, state III or IV disease, no nasal involvement, distant lymph node involvement, and detectable blood levels of EBV DNA) to define patients as low, intermediate, and high risk based on their having 0–1, 2, or 3–5 risk factors, respectively. Overall 3 year survival in these 3 respective groups were 81, 55, and 28%.[25] Patients, particularly those in the advanced poor risk groups may develop hemophagocytic lymphohistiocytosis or have their disease progress to aggressive NK-cell leukemia. Both conditions are life-threatening and far less responsive to treatment.[14]
Treatment
The treatment of ENKTCL- NT employs
- Localized stage I and 2 diseases are treated with a combination of local radiation followed by DeVIC (dexamethasone, etopoxide, ifosfamide, and carboplatin). Five-year progression-free and overall survival rates with this regimen are 70–72% and 61–63%, respectively. An alternative regimen, termed CCRT-VIDL, combines cisplatin plus radiation followed by etopoxide, ifosfamide, cisplatin, and dexamethasone to give complete response and 5 overall survival rates of 87 and 73%, respectively.[16]
- Patients who have a partial response or relapse on this regimen are treated with the SMILE regimen (see below).[16]
- Disseminated stage III and IV disease are treated with SMILE, i.e. dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide. The regimen obtains complete response and 5 year overall survival rates of 45 and 47%, respectively. In the United States, pegaspartase is used in place of L-asparaginase.[16]
- Patients that have a complete or partial response to this regimen may then treated with an autologous stem-cell transplantation regimen, palliative chemotherapy, and/or experimental drugs.[16]
Experimental drugs
There are numerous regimens that use non-chemotherapeutic agents to target specific elements known or thought to be involved in the survival of the malignant cells in a significant percentage of ENKTCL-NT cases. The targets should be determined as overexpressed or present in the malignant tissues of each case before treatment.[16] The targets, therapeutic agents, and some phase 1 clinical trials (testing for appropriate dosages, safety, and side effects) and/or phase 2 clinical trials (testing for efficacy and safety) include:
- PD1: programmed cell death 1 receptor on lymphocytes thereby blocking the action of PD-L1 in suppressing the anti-cancer actions of these cells. Seven patients with refractory or relapsed ENKTCL-NT had either complete (5 patients) or partial (2 patients) responses to Pembrolizumab and three patients with relapsed ENKTCL-NT had had either complete (2 patients) or partial (1 patient) responses to Nivolumab.[25] A clinical study sponsored by the Memorial Sloan Kettering Cancer Center in New York City is recruiting individuals to study the effects of Pembrolizumab in patients with early-stage ENKTCL-NT;[31] a phase I/II clinical study sponsored by the Abramson Cancer Center of the University of Pennsylvania in Philadelphia is recruiting individuals to examine the effects of Pembrolizumab in individuals with relapsed or refractory ENKTCL-NA;[32] and a clinical phase 2 study sponsored by the University of Hong Kong is recruiting individuals to examine the effects of Pembrolizmab on ENKTCL-NT.[33]
- CD30: The malignant cells in ~40% of ENKTCL-NT cases express the surface membrane protein, CD30. Two case reports have indicated that the CD30-targeted monoclonal antibody, which is conjugated to the cytoxic/antineoplastic agent auristatin E, brentuximab vedotin, was helpful in treating relapsed ENKTCL-NT.[25] A not-yet-recruiting study estimated to be finished by Sept., 2018 examines the effects of brentuxixmab vedotin on EBV-positive, CD30-positive lymphomas.[34]
- CD38: CD38 is almost always expressed in the malignant cells of ENkTCL-NT. One patient with this disease, after relapsing following each of two chemotherapy courses, had a complete remission when treated with a cytotoxic antibody directed at CD38, Daratumumab.[11] A phase 2 clinical study on the effects of Daratumumab on ENTCL-NT sponsored by Janssen Research & Development, LLC is recruiting patients in China, South Korea, and Taiwan.[35]
- EBV antigens: EBV-infected cells express the viral LMP1 and LMP2 proteins on their surface membranes and therefore are potential targets for attack by cytotoxic T cells (CTL). Studies have used CTL that have been engineered to attack and kill LMP1 and/or LMP2 expressing cells. Eleven patients with refractory or relapsed ENKTCL-NT were treated with their own CTL that had been engineered to kill LMP1/2-expressing cells. Nine patients had durable (>4 years) remissions, 1 patient had a complete remission which lasted only 9 months, and 2 patients show no response to the treatment. In a second study, 8 patients with localized and two with advanced disease who were in complete remission after chemotherapy (with or without radiation treatment) were given their own CTL that had been engineered to kill LMP1/2-bearing cells. One patient relapsed after 32 months while the remaining 7 patients had progression-free and overall survivals of 100 and 90%, respectively.[25] A phase I clinical trial sponsored by Baylor College of Medicine, the Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and the Methodist Hospital System is recruiting individuals to test the effects of donor CTL engineered to kill cells bearing LMP1/2, ARF, and/or EBNA-1 viral antigens.[36] A phase 2 clinical study sponsored by ViGenCell Inc. is being conducted at the Catholic University of Korea to test the effects of CTL engineered to kill EBV-infected cells on patients that are in complete remission following chemotherapy (±radiation treatment) but at high risk for recurrent disease. Patients will receive the CTL or placebo (i.e. peripheral blood mononuclear cells). The study, which begins recruitment in late Feb., 2019, seeks to determine if the CTL treatment prolongs remissions.[37]
- Bcl-2 proteins: City of Hope Medical Center and the National Cancer Institute to evaluate its effects on refractory and recurrent ENKTCL-NT.[38]
Small molecule inhibitors of
See also
- Cutaneous T-cell lymphoma
- Subcutaneous T-cell lymphoma
- List of cutaneous conditions
- Epstein-Barr virus-associated extranodal NK/T cell lymphoma, nasal type
References
- PMID 34202088.)."
{{cite journal}}
: CS1 maint: multiple names: authors list (link)
- "This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/ - ^ Mario L. Marques-Piubelli, M.D., Carlos A. Torres-Cabala, M.D., Roberto N. Miranda, M.D. "Extranodal NK / T cell lymphoma, nasal type". Pathology Outlines.
{{cite web}}
: CS1 maint: multiple names: authors list (link) Last author update: 5 January 2021. Last staff update: 14 October 2021 - ISBN 978-1-4160-2999-1.
- S2CID 14415645.
- ^ S2CID 52272644.
- S2CID 42534926.
- ^ PMID 28477890.
- ISBN 978-0-7216-2921-6.
- ^ S2CID 47010934.
- ^ S2CID 52051261.
- ^ PMID 29761078.
- ^ PMID 29966370.
- ^ PMID 21628857.
- ^ PMID 28410601.
- PMID 28893938.
- ^ PMID 28679966.
- PMID 28982299.
- ^ PMID 30134235.
- PMID 29518976.
- ^ "CHPF2 chondroitin polymerizing factor 2 [Homo sapiens (human)] – Gene – NCBI".
- ^ "MIR17HG miR-17-92a-1 cluster host gene [Homo sapiens (human)] – Gene – NCBI".
- PMID 18778369.
- PMID 28577912.
- ^ PMID 29149100.
- ^ S2CID 3805195.
- PMID 30212873.
- S2CID 21364706.
- PMID 29592893.
- PMID 21143116.
- ^ add NCCN ref
- ^ "Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type". 12 May 2021.
- ^ "Phase I/II Study of Pembrolizumab in Patients with Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)". 5 May 2021.
- ^ "PD-1 Blockade with Pembrolizumab in Relapsed/Refractory Mature T-cell and NK-cell Lymphomas". 15 April 2019.
- ^ "A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory EBV-and CD30-positive Lymphomas". 31 October 2019.
- ^ "An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients with Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type". 18 December 2020.
- ^ Rouce, Rayne (8 January 2021). "Administration of Most Closely Matched Third Party Rapidly Generated LMP, BARF1 and EBNA1 Specific CytotoxicT-Lymphocytes to Patients With EBV-Positive Lymphoma and Other EBV-Positive Malignancies".
- ^ "A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients". 5 November 2019.
- ^ "A Phase 2 Study of Venetoclax and Romidepsin with Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas". 7 April 2021.